Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid

Shinichiro Okamoto, A. C. Olson, W. R. Vogler, E. F. Winton

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Alkyl-lysophospholipids (ALP) are analogues of 2-lysophosphatidylcholine that have been reported to have selective antitumor activity. These compounds could potentially be useful in purging bone marrow of leukemic cells in autologous marrow transplantation in acute leukemia. To determine the efficacy of pharmacological purging by ALP, we have designed a human assay system to mimic the conditions expected in the clinical setting of autotransplantation using remission marrow. A simulated remission marrow (SRM) was prepared by mixing normal marrow cells and HL60 cells in a ratio of 1,000:1. The effect of cryopreservation on ALP-treated normal, HL60, and SRM cells was examined. In separate experiments, ALP significantly reduced the number of clonogenic HL60 cells with no effect on normal marrow progenitors. The effect of ALP was more apparent after cryopreservation. Incubation of HL60 cells with 50 μg/mL ALP for four hours followed by cryopreservation resulted approximately in a 3 log reduction of clonogenic HL60 cells. ALP also selectively purged the small number of leukemic cells from SRM. In SRM, the data suggested that ALP had indirect cytotoxic activity on leukemic cells by enhancing the cytotoxic activity of monocytes in addition to its direct effect. We found no evidence that clonogenic HL60 cells decreased because of induction of differentiation by ALP. These data indicated that treatment of marrow cells with ALP offers an efficient means to eliminate leukemic cells from the graft.

Original languageEnglish
Pages (from-to)1381-1387
Number of pages7
JournalBlood
Volume69
Issue number5
Publication statusPublished - 1987
Externally publishedYes

Fingerprint

Lysophospholipids
Purging
Bone Marrow
HL-60 Cells
Cryopreservation
Autologous Transplantation
Cells
Lysophosphatidylcholines
Grafts
Bone Marrow Cells
Monocytes
Assays
Bone
Leukemia
Cell Count
Pharmacology

ASJC Scopus subject areas

  • Hematology

Cite this

Okamoto, S., Olson, A. C., Vogler, W. R., & Winton, E. F. (1987). Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid. Blood, 69(5), 1381-1387.

Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid. / Okamoto, Shinichiro; Olson, A. C.; Vogler, W. R.; Winton, E. F.

In: Blood, Vol. 69, No. 5, 1987, p. 1381-1387.

Research output: Contribution to journalArticle

Okamoto, S, Olson, AC, Vogler, WR & Winton, EF 1987, 'Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid', Blood, vol. 69, no. 5, pp. 1381-1387.
Okamoto, Shinichiro ; Olson, A. C. ; Vogler, W. R. ; Winton, E. F. / Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid. In: Blood. 1987 ; Vol. 69, No. 5. pp. 1381-1387.
@article{9057c549e34345368d41e4ea794ab16d,
title = "Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid",
abstract = "Alkyl-lysophospholipids (ALP) are analogues of 2-lysophosphatidylcholine that have been reported to have selective antitumor activity. These compounds could potentially be useful in purging bone marrow of leukemic cells in autologous marrow transplantation in acute leukemia. To determine the efficacy of pharmacological purging by ALP, we have designed a human assay system to mimic the conditions expected in the clinical setting of autotransplantation using remission marrow. A simulated remission marrow (SRM) was prepared by mixing normal marrow cells and HL60 cells in a ratio of 1,000:1. The effect of cryopreservation on ALP-treated normal, HL60, and SRM cells was examined. In separate experiments, ALP significantly reduced the number of clonogenic HL60 cells with no effect on normal marrow progenitors. The effect of ALP was more apparent after cryopreservation. Incubation of HL60 cells with 50 μg/mL ALP for four hours followed by cryopreservation resulted approximately in a 3 log reduction of clonogenic HL60 cells. ALP also selectively purged the small number of leukemic cells from SRM. In SRM, the data suggested that ALP had indirect cytotoxic activity on leukemic cells by enhancing the cytotoxic activity of monocytes in addition to its direct effect. We found no evidence that clonogenic HL60 cells decreased because of induction of differentiation by ALP. These data indicated that treatment of marrow cells with ALP offers an efficient means to eliminate leukemic cells from the graft.",
author = "Shinichiro Okamoto and Olson, {A. C.} and Vogler, {W. R.} and Winton, {E. F.}",
year = "1987",
language = "English",
volume = "69",
pages = "1381--1387",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid

AU - Okamoto, Shinichiro

AU - Olson, A. C.

AU - Vogler, W. R.

AU - Winton, E. F.

PY - 1987

Y1 - 1987

N2 - Alkyl-lysophospholipids (ALP) are analogues of 2-lysophosphatidylcholine that have been reported to have selective antitumor activity. These compounds could potentially be useful in purging bone marrow of leukemic cells in autologous marrow transplantation in acute leukemia. To determine the efficacy of pharmacological purging by ALP, we have designed a human assay system to mimic the conditions expected in the clinical setting of autotransplantation using remission marrow. A simulated remission marrow (SRM) was prepared by mixing normal marrow cells and HL60 cells in a ratio of 1,000:1. The effect of cryopreservation on ALP-treated normal, HL60, and SRM cells was examined. In separate experiments, ALP significantly reduced the number of clonogenic HL60 cells with no effect on normal marrow progenitors. The effect of ALP was more apparent after cryopreservation. Incubation of HL60 cells with 50 μg/mL ALP for four hours followed by cryopreservation resulted approximately in a 3 log reduction of clonogenic HL60 cells. ALP also selectively purged the small number of leukemic cells from SRM. In SRM, the data suggested that ALP had indirect cytotoxic activity on leukemic cells by enhancing the cytotoxic activity of monocytes in addition to its direct effect. We found no evidence that clonogenic HL60 cells decreased because of induction of differentiation by ALP. These data indicated that treatment of marrow cells with ALP offers an efficient means to eliminate leukemic cells from the graft.

AB - Alkyl-lysophospholipids (ALP) are analogues of 2-lysophosphatidylcholine that have been reported to have selective antitumor activity. These compounds could potentially be useful in purging bone marrow of leukemic cells in autologous marrow transplantation in acute leukemia. To determine the efficacy of pharmacological purging by ALP, we have designed a human assay system to mimic the conditions expected in the clinical setting of autotransplantation using remission marrow. A simulated remission marrow (SRM) was prepared by mixing normal marrow cells and HL60 cells in a ratio of 1,000:1. The effect of cryopreservation on ALP-treated normal, HL60, and SRM cells was examined. In separate experiments, ALP significantly reduced the number of clonogenic HL60 cells with no effect on normal marrow progenitors. The effect of ALP was more apparent after cryopreservation. Incubation of HL60 cells with 50 μg/mL ALP for four hours followed by cryopreservation resulted approximately in a 3 log reduction of clonogenic HL60 cells. ALP also selectively purged the small number of leukemic cells from SRM. In SRM, the data suggested that ALP had indirect cytotoxic activity on leukemic cells by enhancing the cytotoxic activity of monocytes in addition to its direct effect. We found no evidence that clonogenic HL60 cells decreased because of induction of differentiation by ALP. These data indicated that treatment of marrow cells with ALP offers an efficient means to eliminate leukemic cells from the graft.

UR - http://www.scopus.com/inward/record.url?scp=0023193472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023193472&partnerID=8YFLogxK

M3 - Article

C2 - 3471282

AN - SCOPUS:0023193472

VL - 69

SP - 1381

EP - 1387

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -